pathway,p_value,effec_size,magnitude,difference,name
WP5089,8.367391466198897e-13,0.43957939089561093,2,-0.534933251063922,Kinin-Kallikrein pathway
WP4153,3.904853653061727e-15,0.4079904044373899,2,-0.420970199357908,"Degradation pathway of sphingolipids, including diseases"
WP4815,1.6724779701928534e-17,0.3487794480088018,2,-0.33404123713015954,Glycosaminoglycan degradation
WP5027,1.1451044149964413e-21,0.32839610325119956,2,0.13101083929134538,nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell
WP3601,2.1918899675931663e-8,0.3013158652266595,2,-0.3009686341901394,Lipid particles composition
WP477,6.388898967108435e-66,0.2617338738797699,1,0.12100184879499892,Cytoplasmic ribosomal proteins
WP3926,9.916462195539953e-6,0.2478401450653514,1,0.12892410767166673,ApoE and miR-146 in inflammation and atherosclerosis
WP4146,7.280419453964493e-5,0.24373794172133761,1,0.2260318170500129,Macrophage markers
WP4788,7.444508071176268e-7,0.2333344734941627,1,0.13895916579998757,Autosomal recessive osteopetrosis pathways
WP107,9.980895468501319e-29,0.22343903895549894,1,0.10303375293238942,Translation factors
WP4462,1.5305036205238615e-4,0.2219857917322676,1,0.1680049610254678,Platelet-mediated interactions with vascular and circulating cells
WP5104,4.392661058079125e-6,0.21624107101793572,1,-0.1999720249903154,Acquired partial lipodystrophy / Barraquer-Simons syndrome
WP3617,1.1886612869460641e-9,0.21396130490252083,1,0.16604248050599665,Photodynamic therapy-induced NF-kB survival signaling
WP4784,1.947213816254248e-7,0.21318690644080762,1,0.14800055865194464,Proteoglycan biosynthesis
WP4804,3.8545546659127743e-4,0.20813830952248122,1,0.1349534676218892,Cholesterol biosynthesis with skeletal dysplasias
WP288,2.9104543198220336e-5,0.20303639100365165,1,0.11201202554350062,Nod-like receptor (NLR) signaling pathway
WP5120,1.0209968161284964e-4,0.19805019368391025,1,0.14900492756295572,Inclusion body myositis
WP3876,0.0010155364117467695,0.1882052976839942,1,-0.1360137702817899,BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation
WP2485,4.805875469983863e-4,0.1812880279143399,1,-0.23797403299621428,"NAD biosynthesis II (from tryptophan)"
WP4936,3.9763912636226515e-7,0.17982307745468856,1,0.09894001419236192,"Perturbations to host-cell autophagy, induced by SARS-CoV-2 proteins"
WP4790,3.233588529765284e-5,0.1702612751211087,1,0.1860051181965809,FGF23 signaling in hypophosphatemic rickets and related disorders
WP4329,1.6876252939820646e-9,0.1698141857427731,1,0.10600491474183057,miRNAs involvement in the immune response in sepsis
WP2916,7.78216821261902e-5,0.16972273652542633,1,0.08705665511444313,Interactome of polycomb repressive complex 2 (PRC2) 
WP2113,0.0025477782211187463,0.16925481195624842,1,0.1039807113378646,Type III interferon signaling
WP4830,0.0016979357152086402,0.16924900783303393,1,-0.18905676494471196,GDNF/RET signaling axis
WP4518,0.002812436606059132,0.1675679036417814,1,-0.263614860476282,"Gamma-glutamyl cycle for the biosynthesis and degradation of glutathione, including diseases"
WP3,1.9942978986700856e-05,0.1674452030774298,1,0.166046991641244,Transcriptional activation by NRF2 in response to phytochemicals
WP2805,0.005381925170028017,0.1669742627758788,1,0.08999551085049276,exRNA mechanism of action and biogenesis
WP5021,1.0460647341724907e-18,0.16663529177960584,1,0.10305776174269646,SARS-CoV-2 Infection
MINERVA Coagulation pathway,2.2159674955260622e-40,0.16631680672613086,1,-0.20702962678970444,MINERVA Coagulation pathway
WP4210,2.7777590944369097e-5,0.16619131919073252,1,-0.22106603330590224,Tryptophan catabolism leading to NAD+ production
WP47,0.007030814564546988,0.16562753183626133,1,0.1410459600121355,Hedgehog signaling pathway Netpath
WP4922,1.1876000214369035e-10,0.1643446621171315,1,0.1700335129715713,Mitochondrial complex IV assembly
WP2112,1.7126145530916522e-7,0.1636214255065182,1,0.08396551270143293,IL-17 signaling pathway
WP4357,3.9156466663195543e-7,0.15884568810417607,1,0.1240673167135638,NRF2-ARE regulation
WP2290,1.5474409409771864e-4,0.15670013172191513,1,0.08702960426668241,RalA downstream regulated genes
WP5109,2.5468187085569093e-4,0.15498511844056667,1,-0.14602834699459058,Familial hyperlipidemia type 2
WP2895,0.006014560365663643,0.1540789479365498,1,0.17499315000837762,Differentiation of white and brown adipocyte
WP4921,9.727969764775642e-5,0.15299013128845787,1,0.12801032914516286,Mitochondrial complex III assembly
WP4947,8.647900656781811e-4,0.1527002108949769,1,-0.12696623785168654,Nitric oxide metabolism in cystic fibrosis
WP3529,1.950001163350115e-4,0.15097084513618786,1,0.15001452319528535,Zinc homeostasis
WP3613,1.6080261885647467e-5,0.15054214384299097,1,0.10103461582049224,Photodynamic therapy-induced unfolded protein response
WP111,1.5288833145557427e-23,0.1503415873992832,1,0.158972255449826,Electron transport chain: OXPHOS system in mitochondria
WP4723,0.005287517867355763,0.1476364497752056,1,0.11403987380095898,Omega-3 / omega-6 fatty acid synthesis
WP558,2.1640580937474374e-13,0.1455194176888599,1,-0.17100312834369819,Complement and coagulation cascades
WP5044,5.531406786142986e-4,0.14479391460355875,1,-0.17405871009412316,Kynurenine pathway and links to cell senescence
WP3580,4.503679578985957e-6,0.14454185379201745,1,-0.18200394904616984,Methionine de novo and salvage pathway
WP4873,0.03793657153217368,0.1426288045863872,1,-0.14791727493480938,Peroxiredoxin 2 induced ovarian failure
WP4480,0.007604957580602495,0.13860017126871296,1,0.08000263264599634,Altered glycosylation of MUC1 in tumor microenvironment
WP4920,0.010454148138612961,0.13828099354588033,1,0.17006102865156858,Mitochondrial complex II assembly
WP545,6.946545405592211e-6,0.13723682324205425,1,-0.14296734684747062,Complement activation
WP623,1.240298324486035e-12,0.13590266650455948,1,0.1330259197743662,Oxidative phosphorylation
WP516,0.006374233358207316,0.13474196688945944,1,0.11404438361377953,Hypertrophy model
WP5020,1.3526077433774504e-9,0.13376855777688523,1,0.08494156638266256,SARS-CoV-1 Infection
WP4222,1.562939323133431e-5,0.1335006898312134,1,-0.13005005078176324,Phosphodiesterases in neuronal function
WP1455,0.013997856031374958,0.1325201166417708,1,0.14599236077453814,Serotonin transporter activity
WP4844,3.2500387492535147e-05,0.1284191238672663,1,0.09397720316400206,Influence of laminopathies on Wnt signaling
WP170,0.0035386844124812742,0.12828549128201344,1,-0.14295594228250413,Nuclear receptors
WP4224,3.1886274134600944e-5,0.127763050017451,1,-0.11995643723577996,Purine metabolism and related disorders
WP5110,0.0054568936647043185,0.12724598255447325,1,-0.11197356489137181,Familial hyperlipidemia type 3
WP4558,0.0027585576166071295,0.12684760133485976,1,0.08298800645905326,Overview of interferons-mediated signaling pathway
WP411,2.4101103016767065e-22,0.12374978892371939,1,0.06604328657537706,mRNA processing
WP4206,7.31557220582726e-4,0.12078401292080797,1,0.09301454161893556,Hereditary leiomyomatosis and renal cell carcinoma pathway
WP4157,0.03165392174162908,0.12053178979421916,1,-0.15094331953810602,GABA metabolism (aka GHB)
WP3658,0.005708432023551683,0.12019008692292922,1,0.07792315989418272,Wnt/beta-catenin signaling pathway in leukemia
WP4142,0.009880913601894326,0.11978882728641417,1,0.09198083637146626,Metabolism of spingolipids in ER and Golgi apparatus
WP561,0.013870132709759347,0.11951781680326345,1,-0.10599576270222591,Heme biosynthesis
WP4792,0.0026739277883370506,0.11908289383080795,1,-0.10500098350869491,Purine metabolism
WP4324,1.1137170044077035e-9,0.11890802887388219,1,0.11404054681917934,Mitochondrial complex I assembly model OXPHOS system
WP2374,1.0820661797093832e-9,0.1184130640625005,1,0.07495961715555974,Oncostatin M signaling pathway
WP134,0.02330804375871424,0.11779293216335514,1,-0.10296058065993498,Pentose phosphate metabolism
WP4521,8.118358352136329e-4,0.11774051043662323,1,0.0630207500052974,Glycosylation and related congenital defects
WP4856,9.875327983064774e-5,0.11537290594063561,1,0.08195068584830997,Intracellular trafficking proteins involved in CMT neuropathy
WP5094,1.6406198968123706e-9,0.11346957833815101,1,0.11391865059407033,Orexin receptor pathway
WP2864,2.3066226356808524e-6,0.11252157354631687,1,0.08202405855375895,Apoptosis-related network due to altered Notch3 in ovarian cancer
WP5112,0.017267067490345626,0.11213330324070127,1,-0.08707571280936634,Familial hyperlipidemia type 5
WP4724,0.029104301031754074,0.11181563271304211,1,0.10801147300458672,Omega-9 fatty acid synthesis
WP4879,1.775194768885432e-6,0.1113762802814776,1,0.08797986808509028,Overlap between signal transduction pathways contributing to LMNA laminopathies
WP4301,6.273706101595166e-4,0.11071426433193374,1,0.058931722918702065,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
WP2865,0.002607236312239183,0.1105295198391928,1,0.09904717697684483,IL1 and megakaryocytes in obesity
WP438,0.038804916817632554,0.10938577638351325,1,0.052042413486766,Non-homologous end joining
MINERVA Electron Transport Chain disruption,2.4701026991030583e-28,0.10904888865402987,1,0.10803004552228622,MINERVA Electron Transport Chain disruption
WP272,9.911700532144604e-4,0.10886824287480398,1,-0.14007204505751936,Blood clotting cascade
WP3630,0.021761637559123973,0.10806164408742533,1,0.08999099328401401,"NAD metabolism, sirtuins and aging"
MINERVA Interferon lambda pathway,5.610991980308881e-11,0.10700827747416475,1,0.06505329564804344,MINERVA Interferon lambda pathway
WP2881,0.025265589434973063,0.1053689252370755,1,0.14094218192285252,Estrogen receptor pathway
WP3611,3.789758711062939e-5,0.1050554837836557,1,0.07503416825371666,Photodynamic therapy-induced AP-1 survival signaling.
WP4718,3.4820219166989463e-5,0.10480503662132795,1,0.07295723889265623,Cholesterol metabolism with Bloch and Kandutsch-Russell pathways
WP78,0.0018742293868428085,0.10441038938696628,1,0.10304920759457994,TCA cycle (aka Krebs or citric acid cycle)
WP129,0.004627608712890465,0.103068775602935,1,0.11701190183964634,Matrix metalloproteinases
WP5097,2.3291305698926296e-4,0.10211599560421052,1,0.10203646369657562,CCL18 signaling pathway
WP4742,0.0497667305671493,0.1018862764464056,1,0.08693499986007049,Ketogenesis and ketolysis
WP4241,6.9900775956333e-4,0.0998372853731317,1,0.0820388111976511,Type 2 papillary renal cell carcinoma
WP3614,3.843723348547772e-4,0.09955576155176497,1,0.09495836245061255,Photodynamic therapy-induced HIF-1 survival signaling
WP734,0.009153202102671239,0.09929890337868669,1,-0.05796357650375826,Serotonin receptor 4/6/7 and NR3C signaling
WP4880,1.6337314059422614e-4,0.09920720662085195,1,0.060078078487447825,Host-pathogen interaction of human coronaviruses - interferon induction
WP5101,0.00937615860703413,0.09905640151147606,1,0.08803613077098152,Congenital generalized lipodystrophy (CGL)
WP3858,0.001365846532200292,0.09900090171278231,1,0.0519976756956861,Toll-like receptor signaling related to MyD88
WP4726,0.006344878923270802,0.09849502405828453,1,0.07805097269106608,Sphingolipid metabolism: integrated pathway
WP4725,0.006344878923270802,0.09849502405828453,1,0.07805097269106608,Sphingolipid metabolism overview
WP3584,1.4221024094177108e-5,0.09836782001728411,1,0.0760001319375466,MECP2 and associated Rett syndrome
WP619,0.0013244225973087396,0.09797214604839295,1,0.07695096796842335,Type II interferon signaling (IFNG)
MINERVA Endoplasmatic Reticulum stress,1.0765634005215102e-17,0.09794368112837717,1,0.06897472870079574,MINERVA Endoplasmatic Reticulum stress
WP4478,0.0325253665500079,0.0979032883489626,1,0.056026470464445,LTF danger signal response pathway
WP2011,0.02659555319688984,0.09781912297793133,1,0.07901239936201174,SREBF and miR33 in cholesterol and lipid homeostasis
MINERVA JNK pathway,0.0016717828637167708,0.09774861330891874,1,0.0620189116405126,MINERVA JNK pathway
WP4300,0.013706265407697392,0.09676321703254054,1,0.10694054926046329,Extracellular vesicles in the crosstalk of cardiac cells
WP1422,0.002391363379280703,0.09632381025035819,1,0.07796302709672204,Sphingolipid pathway
WP4571,0.037676737481850055,0.0952771303692227,1,0.058081284227829995,Urea cycle and related diseases
WP4629,0.016982347695201423,0.09466318521110795,1,-0.09105986686555484,Aerobic glycolysis
WP2817,0.007667043783121545,0.09445410910268329,1,0.1020222529204833,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4)
WP4522,0.01244278026273922,0.09427138811779671,1,-0.0959611084404376,"Metabolic pathway of LDL, HDL and TG, including diseases"
WP4969,0.0027061234825706735,0.09274011104486143,1,-0.10893878219570483,RAS and bradykinin pathways in COVID-19
WP430,0.002235269264181197,0.09272612205729977,1,-0.08204410946352747,Statin inhibition of cholesterol production
WP410,4.0245403978483575e-4,0.09229212100264512,1,0.07601545819735087,Exercise-induced circadian regulation
WP3612,0.0030153511639545087,0.09224683408720218,1,0.10999593149316067,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling
WP4396,2.879166128726671e-12,0.09063377489777033,1,0.08598212791507288,Nonalcoholic fatty liver disease
MINERVA Nsp4 and Nsp6 protein interactions,2.2707364077432597e-7,0.09034421283826316,1,0.09998634520422556,MINERVA Nsp4 and Nsp6 protein interactions
WP368,0.007088018968280057,0.0897106352053141,1,0.08994824897248477,Mitochondrial long chain fatty acid beta-oxidation
WP4923,8.270985677337907e-4,0.08920316832064729,1,0.04894156993153877,Autophagy
WP3851,0.006116040074573411,0.08757758862328333,1,0.04398392734799375,TLR4 signaling and tolerance
WP554,0.04010718477209687,0.0871415446650968,1,-0.11204970749959463,ACE inhibitor pathway
WP4816,3.3650887122959857e-4,0.08711484538436429,1,0.07494567799743566,TGF-beta receptor signaling in skeletal dysplasias
WP615,2.0078482735990032e-7,0.08595412227815101,1,0.06605957172490522,Senescence and autophagy in cancer
WP2018,2.6875650393076807e-5,0.08573671703918533,1,0.05407845558845099,RANKL/RANK signaling pathway
WP2447,4.850937844448153e-4,0.08540068835073074,1,-0.06998010918391898,Amyotrophic lateral sclerosis (ALS)
WP3869,0.007984051475878462,0.08531033754758802,1,-0.07104396955714731,Cannabinoid receptor signaling
WP4320,0.007766192400868064,0.08282985713774238,1,0.0589757245912603,Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome
WP197,0.02394965267943059,0.08218104366010175,1,0.048015004511811274,Cholesterol biosynthesis pathway
WP560,0.0010669756311990014,0.08175641810812827,1,0.06693834769096428,TGF-beta receptor signaling
WP4786,0.009077915204507547,0.08118198068926442,1,0.06592607250186952,Type I collagen synthesis in the context of osteogenesis imperfecta
WP466,0.0038266800973097864,0.08112477486740288,1,0.056927057093511826,DNA replication
WP405,6.07624420741448e-4,0.08080428241427218,1,0.04694769198107337,Eukaryotic transcription initiation
WP4721,0.022914065413855704,0.08063612917902857,1,-0.09604455290725497,Eicosanoid metabolism via lipooxygenases (LOX)
WP4288,0.021194442087864078,0.07918867575340055,1,-0.07195795706870636,MTHFR deficiency
WP2533,0.007108503011077376,0.07883061242080303,1,0.06597813382304421,Glycerophospholipid biosynthetic pathway
WP61,5.730649682314787e-4,0.07882649798471844,1,0.0489756902058562,Notch signaling pathway (Netpath)
WP1528,0.015305934312424127,0.07798847285038815,1,-0.049925141806093434,Physiological and pathological hypertrophy of the heart
WP1471,0.002122624149751802,0.07771823550343354,1,0.051008325903321425,Target of rapamycin (TOR) signaling
WP4482,0.023304664144352293,0.07735676992498386,1,-0.044048671768751727,Vitamin D in inflammatory diseases
WP1539,0.01279206215902373,0.07697789064296094,1,0.0650455532832983,Angiogenesis
WP2036,0.0020719016142371994,0.0765887698928527,1,0.04000789422744015,TNF-related weak inducer of apoptosis (TWEAK) signaling pathway
WP2878,0.015448384855918207,0.07582963012502537,1,-0.0880539014882974,PPAR-alpha pathway
WP400,0.005602856510835123,0.07536830599748326,1,0.042030683238319426,p38 MAPK signaling pathway
WP3981,0.007520629667354344,0.07533164423022824,1,-0.03903805500784434,miRNA regulation of prostate cancer signaling pathways
MINERVA HMOX1 pathway,6.399567548106221e-8,0.0738783674816153,1,-0.06792839364071276,MINERVA HMOX1 pathway
WP262,0.03258021528741542,0.07339740795402677,1,0.037009226165009165,Ebstein-Barr virus LMP1 signaling
WP2431,8.75786381921687e-5,0.072993478127210007,1,0.07904466457329382,Spinal cord injury
WP4719,0.019903095723602514,0.07286557742507624,1,-0.0789486615562478,Eicosanoid metabolism via cyclooxygenases (COX)
WP3844,0.006631636816658653,0.07281839850140169,1,0.04298554141597292,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
WP1946,0.04718327879630653,0.07039403950961082,1,-0.06703003808282161,Cori cycle
WP4217,2.2643214692195182e-7,0.07031589618745254,1,0.0610458308640523,Ebola virus pathway in host
WP5053,0.03313217651272051,0.0699782746881032,1,-0.09002634650409568,Development of ureteric collection system
MINERVA Orf10 Cul2 pathway,1.5715710647921412e-8,0.06940682035492143,1,-0.041946992060651174,MINERVA Orf10 Cul2 pathway
WP2636,0.013980762578569299,0.06891432380504958,1,-0.0530034973497313,Common pathways underlying drug addiction
WP2203,0.0038904860481591744,0.06852372366233181,1,0.042948438438625294,Thymic stromal lymphopoietin (TSLP) signaling pathway
MINERVA Orf3a protein interactions,7.958198147467117e-5,0.06737116798004714,1,0.043042326004982305,MINERVA Orf3a protein interactions
WP408,0.01594987058810014,0.06723424340176942,1,0.08395400378420625,Oxidative stress response
WP2369,0.023365638486343543,0.06683572862116194,1,-0.05693223637831588,Histone modifications
WP2849,0.044195023118330276,0.06563600541687895,1,0.06497345013411507,Hematopoietic stem cell differentiation
WP3865,0.0013629714816321995,0.06539618619713135,1,0.03798571575590223,Novel intracellular components of RIG-I-like receptor (RLR) pathway
WP4008,0.015614205790491357,0.06485259594593194,1,-0.062023572039274166,NO/cGMP/PKG mediated neuroprotection
WP2446,0.0015028586364211102,0.06447074295287875,1,0.04801657362673481,Retinoblastoma gene in cancer
WP3624,0.01825344523940941,0.06393778458589791,1,0.08495942858602679,Lung fibrosis
WP4336,0.01901547519828637,0.06261362625747909,1,-0.049999060378232874,ncRNAs involved in Wnt signaling in hepatocellular carcinoma
WP5038,0.029621251207986615,0.06164737852235804,1,0.04595558108261568,Mitochondrial immune response to SARS-CoV-2
WP716,0.027990247173104964,0.06159070962081029,1,-0.06492267019430152,Vitamin A and carotenoid metabolism
WP4258,0.014054966765126001,0.0611119836319963,1,-0.04605761018822589,lncRNA in canonical Wnt signaling and colorectal cancer
WP4871,0.02030440872243984,0.06105098221702143,1,-0.046043646018338054,Kisspeptin/kisspeptin receptor system in the ovary
WP2038,0.008954668499207445,0.06090203533168003,1,0.04291597279117273,Microtubule cytoskeleton regulation
WP236,7.999805374309602e-4,0.05961573153984129,1,0.05896832942630752,Adipogenesis
WP3594,6.296969708403828e-5,0.05917145817483236,1,0.04600759364637059,Circadian rhythm genes
MINERVA Interferon 1 pathway,1.792260899854031e-5,0.058262495369567666,1,0.038010027741431515,MINERVA Interferon 1 pathway
WP2371,0.030226451174132262,0.057571776015396384,1,-0.04503697844847585,Parkinson's disease pathway
WP3940,0.007668949649181179,0.05738386377825293,1,-0.06998398581869207,One-carbon metabolism and related pathways
WP2880,0.023876130507188356,0.05667449538476864,1,0.053964775497697834,Glucocorticoid receptor pathway
WP1449,3.803065353149383e-4,0.056184185563308175,1,0.036975964797986496,Regulation of toll-like receptor signaling pathway
WP2840,0.02178500410645372,0.056155642108111664,1,0.05105523700127271,Hair follicle development: cytodifferentiation - part 3 of 3
WP3680,0.007320189135546195,0.05506718153142848,1,-0.04094201330570589,Physico-chemical features and toxicity-associated pathways
MINERVA Nsp14 and metabolism,3.7110190034155964e-4,0.05424288518316667,1,-0.05497872172168026,MINERVA Nsp14 and metabolism
WP2877,2.972822408979906e-4,0.05397101610881576,1,0.06705888793661305,Vitamin D receptor pathway
WP465,0.026338980996397424,0.05393619825498747,1,-0.07192555467090987,Tryptophan metabolism
WP395,0.01435894996321562,0.05383573249158488,1,0.03605415956831313,IL-4 signaling pathway
WP4136,0.041148056927019123,0.05302809794811028,1,0.040016650790548836,Fibrin complement receptor 3 signaling pathway
MINERVA PAMP signalling,5.399375942272469e-5,0.05258786619166143,1,0.026949804828203156,MINERVA PAMP signalling
MINERVA NLRP3 inflammasome activation,0.004826727207914921,0.05127750650624086,1,-0.043004294484334425,MINERVA NLRP3 inflammasome activation
WP428,0.00762283778492068,0.05073622852608511,1,-0.04303580463357735,Wnt signaling
WP2324,0.005636056604099156,0.05036527590783221,1,0.03704761743983062,AGE/RAGE pathway
WP4963,0.031089617020788333,0.05005766073511032,1,0.04599334720811215,p53 transcriptional gene network
WP2059,1.4318329331891521e-6,0.049876700398173233,1,0.0350206597458387,Alzheimer's disease and miRNA effects
WP4932,0.0012958426725582241,0.04979239239410287,1,0.04501622118603189,7q11.23 copy number variation syndrome
WP474,0.03994057472455572,0.04824898329995404,1,0.052965042074596916,Endochondral ossification
WP4808,0.03994057472455572,0.04824898329995404,1,0.052965042074596916,Endochondral ossification with skeletal dysplasias
WP183,0.010772093030519481,0.04723086567959349,1,0.02600797832040202,Proteasome degradation
WP534,0.03599278330936033,0.04498604392303535,1,-0.056032890435049026,Glycolysis and gluconeogenesis
WP5124,1.8005990665802123e-5,0.04472063348491243,1,0.0319751408790845,Alzheimer's disease
WP2380,0.0010402360411251625,0.044016097921435106,1,0.031958518983971396,Brain-derived neurotrophic factor (BDNF) signaling pathway
WP5055,0.02381992034761816,0.04369740879894864,1,0.05205941202240547,Burn wound healing
WP4754,1.2703122868690649e-4,0.04251911125921229,1,0.040021099889423976,IL-18 signaling pathway
WP3888,9.673995728783241e-9,0.04222586474593871,1,0.03208217049664992,VEGFA-VEGFR2 signaling pathway
WP2037,0.02050532461243826,0.04179002150795558,1,0.026008504183624718,Prolactin signaling pathway
WP4659,0.007306856738922433,0.04002450211905731,1,0.026034969539945038,Gastrin signaling pathway
WP2034,0.020635642207518776,0.03997236935300606,1,0.025990543173322063,Leptin signaling pathway
WP75,0.04161143863899783,0.03853785042086625,1,0.02199343736567535,Toll-like receptor signaling pathway
WP1544,0.03185372609550827,0.0381440858593861,1,-0.02594385202267517,MicroRNAs in cardiomyocyte hypertrophy
WP2355,0.03466527638028997,0.03605576702585395,1,0.03297835715572946,Corticotropin-releasing hormone signaling pathway
WP2882,4.3448979007826717e-4,0.0353307078148356,1,0.04106406024171109,Nuclear receptors meta-pathway
WP4946,0.03615139327878537,0.0339267747731178,1,-0.02100279666434874,"DNA repair pathways, full network"
WP1984,0.014088032956267796,0.03368101421705193,1,0.022943212367060515,Integrated breast cancer pathway
WP4549,0.03071109942044305,0.03192188793380818,1,0.022028313275166213,Fragile X syndrome
WP2884,0.03010838609501296,0.031762005982892264,1,0.04197938734434759,NRF2 pathway
WP3915,0.02927735809394686,0.030972119993865285,1,0.020996377859329025,Angiopoietin-like protein 8 regulatory pathway
WP289,0.0327825388754417,0.030831700309466428,1,-0.03203844981216386,Myometrial relaxation and contraction pathways
MINERVA Nsp9 protein interactions,0.0025090683242453868,0.028231755051970037,1,0.020967357422507802,MINERVA Nsp9 protein interactions
WP4352,0.0058838584352918204,0.02810542612177261,1,0.019968949659873926,Ciliary landscape
WP437,0.036134038272347395,0.024822674239261867,1,0.01796404048986781,EGF/EGFR signaling pathway
